![]() ![]() Glycemic AssessmentĪ1C reflects average glycemia over approximately 3 months. ![]() Individuals on a variety of insulin regimens can benefit from CGM with improved glucose control, decreased hypoglycemia, and enhanced self-efficacy (Section 7, “Diabetes Technology,” ) ( 1). CGM serves an increasingly important role in the management of the effectiveness and safety of treatment in many patients with type 1 diabetes and in selected patients with type 2 diabetes. Individual glucose monitoring (discussed in detail in Section 7, “Diabetes Technology,” ) is a useful tool for diabetes self-management, which includes meals, exercise, and medication adjustment, particularly in individuals taking insulin. A1C is the metric used to date in clinical trials demonstrating the benefits of improved glycemic control. Glycemic control is assessed by the A1C measurement, continuous glucose monitoring (CGM) using either time in range (TIR) and/or glucose management indicator (GMI), and blood glucose monitoring (BGM). ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |